PharmaFocus Today – Page 22 – media

AnLingKe Biotechnology has completed a $42 million Series A financing to accelerate the global development of bispecific antibodies and ADC products

Allink Biotherapeutics announced today the completion of a $42 million Series A funding round. This round of financing is led by Lanchi Venture Capital, with follow-up investments from Yuansheng Venture Capital, Junlian Capital, and Jianfa Emerging Investment, as well as additional investments from existing shareholders Gao Rong Venture Capital and Mi Fang Health Fund. Gaorong Venture Capital co led the angel round of investment in AnLingKe Biotechnology in 2023. AnLingKe Biotechnology was founded in 2023 and is a biotechnology company focused on innovative drug research and development. Based on its independently developed bispecific antibody and ADC technology platform, the company has laid out a series of innovative product pipelines with the potential for first in class (FIC) and best in class (BIC). The company is committed to developing breakthrough therapies in the fields of oncology and immune diseases, bringing innovative treatment options to patients worldwide. AnLingKe Biology has established an ...
- Source: drugdu
- 83
- November 29, 2024
Kolombotai Biotechnology has obtained the TROP2 ADC drug; Two new drugs from Huadong Pharmaceutical have been approved for market | Early Reference Medicine

On November 27, Kelenbotai Biology announced that the company’s first antibody drug conjugate (ADC) targeting human trophoblast surface antigen 2 (TROP2) for unresectable local advanced or metastatic triple negative breast cancer (TNBC) adult patients who have received at least two kinds of systematic treatment in the past (at least one of which is for advanced or metastatic stage), sac-TMT (formerly SKB264/MK-2870) (Gatalay), was approved by the State Food and Drug Administration to be listed in China. This drug is the first domestically produced and the second globally approved TROP2 ADC drug. Comment: This incident has certain significance for both the company and the domestic innovative pharmaceutical industry. China has become a core participant in global ADC research and development. There are companies in China with strong ADC technology platforms, companies that have accumulated differentiated ADC clinical drugs and strong commercialization capabilities, or companies that have comprehensive and rich technical capabilities ...
- Source: drugdu
- 92
- November 29, 2024
Boston Scientific’s second acquisition this month

On November 25, 2024, Boston Scientific announced that it would acquire infusion pump manufacturer Intera Oncology for an undisclosed amount. Intera Oncology has developed the Intera 3000 hepatic artery infusion pump and chemotherapy drug fluorouridine. Both have obtained FDA approval. This pump can be used for hepatic arterial infusion (HAI) therapy to treat liver tumors mainly caused by metastatic colorectal cancer. The Intera 3000 is the only approved constant current implantable pump for HAI treatment in the United States. 01. Only approved in the United States Intera Oncology is a rapidly growing Boston life sciences company with a mission to change the course of cancer in patients with colorectal and cholangiocarcinoma. Founded by two doctors in 2019, their shared vision is to improve the survival rate of patients with colorectal cancer liver metastases and cholangiocarcinoma by ensuring access to hepatic arterial infusion (HAI) therapy. Hepatic arterial infusion (HAI) therapy is ...
- Source: drugdu
- 67
- November 29, 2024
Two innovative medical devices have been approved for market launch

Recently, the National Medical Products Administration approved the registration applications for two innovative products, the “implantable cardiac pacing electrode lead” of Chuangling Heart Rhythm Management Medical Equipment (Shanghai) Co., Ltd. (hereinafter referred to as “Chuangling Heart Rhythm Medical”) and the “zirconia ceramic femoral head” of Beijing Ansong Technology Co., Ltd. (hereinafter referred to as “Ansong Technology”). Chuangling Heart Rhythm Medical, the first domestically produced product launched Chuangling Heart Rhythm Medical was established in 2014, dedicated to the research and development, manufacturing, and management of medical devices related to heart rhythm diseases, providing corresponding technical services and consulting, and conducting sales and import/export business of medical devices. The company strives to become the preferred brand for domestic pacemakers, providing high-quality heart rhythm management products and services for patients in China and even the world, improving their quality of life, and extending their lifespan. The BonaFire approved this time ® Implantable cardiac ...
- Source: drugdu
- 76
- November 29, 2024
Amgen’s weight loss drug has a 20% weight loss effect, but the side effects are high, and the stock price once plummeted by 12.3%!

Today, Amgen announced the positive results of its weight loss therapy MariTide in a 52-week clinical phase 2 study. Analysis shows that in obese or overweight people without type 2 diabetes, MariTide achieved an average weight loss of about 20% in week 52, and there was no weight loss plateau, indicating that patients may lose weight further after treatment for more than 52 weeks. While weight loss drug companies generally rose, Amgen once plummeted by more than 12.3% because although the efficacy of Amgen’s MariTide weight loss drug met Wall Street expectations, it had high side effects and failed to beat Eli Lilly’s blockbuster drug Zepbound, and the trial results were lower than Wall Street’s high expectations for MariTide. In a one-year trial, non-diabetic patients took Amgen’s MariTide once a month or less frequently and lost up to 20% of their weight. Wegovy’s late-stage study showed a 15% weight loss ...
- Source: drugdu
- 69
- November 29, 2024
“Innovative Cardiac Tissue Ablation Clip” approved by CE

AtriCure, a leading company in the treatment of atrial fibrillation, announced today that its EnCompass cardiac tissue ablation clip has received the EU CE mark, meaning the device can be sold in more than 30 countries in the European Economic Area (EEA). A number of innovative products were launched AtriCure was founded in 2000 and focuses on cardiac surgery solutions. The company mainly produces and sells cardiac ablation devices, providing innovative technologies for the treatment of atrial fibrillation and related diseases. At present, AtriCure has 138 authorized patents in the United States and has served more than 300,000 patients with atrial fibrillation since 2004. It is understood that the EnCompass cardiac tissue ablation clamp is used for cardiac tissue ablation surgery, including comprehensive epicardial ablation of the left atrium during open heart surgery. This is a simpler and faster method of open-chest cardiac ablation, allowing doctors to perform comprehensive epicardial ...
- Source: drugdu
- 62
- November 29, 2024
59.1 billion autoimmune dual-antibody therapy market has seen international giants take action

The layout of bispecific antibodies in the field of tumors has become mature, but in the field of autoimmune diseases, the layout of bispecific antibodies is relatively small. The first batch of enlightened MNCs have begun to take action. Recently, autoimmune bispecific antibody therapy has increasingly become the focus of new drug research and development. Many pharmaceutical giants such as Johnson & Johnson, Sanofi, and Roche have chosen to deploy in the field of autoimmune bispecific antibodies, with a total of more than US$8.15 billion (approximately RMB 59.1 billion) in mergers and acquisitions and related drug transactions. The track of autoimmune bispecific antibody therapy has changed. Sanofi, Merck, and Roche: Grabbing the beachhead of CD3 bispecific antibodiesCD3 is closely related to the activation of T cells. By combining CD3 and tumor-associated antigens, it can guide and activate T cells to approach and kill tumor cells. At present, most of the ...
- Source: drugdu
- 68
- November 29, 2024
Promote the sinking of drugs for common chronic diseases to the grassroots level

Due to some chronic and common diseases, patients come to township health centers and community health service centers for treatment, but are told that ‘there is no medicine’. In response to the problem of difficult medication at the grassroots level, the National Health Commission and six other departments recently jointly issued the “Opinions on Reforming and Improving the Grassroots Drug Linkage Management Mechanism to Expand the Types of Grassroots Drugs”, striving to smooth the channels for drug connection between urban and rural areas, counties and townships, enhance the ability of grassroots drug allocation and use, and meet the basic medication needs of the masses. Expand types Make the medicine at the doorstep more comprehensive The proportion of grassroots diagnosis and treatment in China has reached 52% by 2023. However, some medical staff have previously reported that there are few types of drugs available at the grassroots level, limited space for ...
- Source: drugdu
- 82
- November 28, 2024
No need for injections! MIT scientists develop spray capsules that mimic squid inkjet technology, with the potential to revolutionize drug delivery methods

More than 300 years ago, British architect and scientist Sir Christopher Wren became interested in drug delivery, hoping to find a way to directly inject drugs or liquids into the human body. He made a simple syringe using tools such as goose feathers and metal tubes, and for the first time attempted to inject drug solution into a dog’s veins through injection. Since then, “injection” has gradually become a widely used method of drug delivery. Today, many large molecule biologics, such as recombinant insulin, monoclonal antibodies, and vaccines, are mainly injected into the human body to exert their therapeutic effects. However, the pain and trouble caused by injection are self-evident, especially when treating chronic diseases such as diabetes or cancer that require frequent medication, injection has brought considerable burden to patients’ daily life. So, in recent years, many scientists have been actively seeking innovative methods for drug delivery systems: without ...
- Source: drugdu
- 89
- November 28, 2024
BD Trading and IPO of Chinese Innovative Preparations

1. Jimu Biological License: Tian Tian Pharmaceutical ARVN001 600 million yuan On November 13th, Tian Shan Pharmaceutical and Ji Mu Biotechnology announced that Ji Mu Biotechnology has authorized Tian Shan Pharmaceutical with exclusive commercial rights for its ARVN001 (Triamcinolone Acetonide Choroidal Injection Suspension) under development in mainland China. ARVN001 uses a suprachoroidal microinjection (SCS microinjection) system ®） The patented technology will be used to treat uveitis related macular edema (UME) and other potential ophthalmic indications under development. Jimu Biotech will receive a total down payment and milestone payments of up to 85 million US dollars (approximately 600 million RMB). Previously, Jimu Biotechnology obtained the rights to develop and commercialize this therapy in the Asia Pacific region from Clearside Biomedical Inc. In July 2024, Jimu Biotechnology announced that ARVN001 achieved positive top line results in the Phase III clinical trial of UME in China. Meanwhile, research on the use of this ...
- Source: drugdu
- 63
- November 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.